A Common Biological Mechanism in Cancer and Alzheimers Disease?
Open accessThe DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Abstract
Cancer and Alzheimer's disease (AD) are two common disorders for which the final pathophysiological mechanism is not yet clearly defined. In a prospective longitudinal study we have previously shown an inverse association between AD and cancer, such that the rate of developing cancer in general with time was significantly slower in participants with AD, while participants with a history of cancer had a slower rate of developing AD. In cancer, cell regulation mechanisms are disrupted with augmentation of cell survival and/or proliferation, whereas conversely, AD is associated with increased neuronal death, either caused by, or concomitant with, beta amyloid (Abeta) and tau deposition. The possibility that perturbations of mechanisms involved in cell survival/death regulation could be involved in both disorders is discussed. Genetic polymorphisms, DNA methylation or other mechanisms that induce changes in activity of molecules with key roles in determining the decision to "repair and live"- or "die" could be involved in the pathogenesis of the two disorders. As examples, the role of p53, Pin1 and the Wnt signaling pathway are discussed as potential candidates that, speculatively, may explain inverse associations between AD and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Mice engineered to be deficient in p53 are developmentally normal, but susceptible to spontaneous tumors [24].”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 1×
“The maintenance of tissue homeostasis is achieved by efficient mechanisms that control genomic stability to prevent aberrant proliferation [16,17,18].”
BackgroundParker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1996) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.46.1.5 · Cited by 1,759
Ink4a/Arf expression is a biomarker of aging
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., & Sharpless, N. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22475 · Cited by 1,486 · cited 1×
“On the other hand, increased levels of p16 expression and of the incidence of p16-positive cells are associated with age in many mouse and rat tissues [48,49].”
Backgroundp53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 2×
“Tyner et al [26] created transgenic mice with a p53-mutation that confers phenotypes consistent with an activated form of p53.”
BackgroundStem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a
Janzen, V., Forkert, R., Fleming, H. E., Saito, Y., Waring, M. T., Dombkowski, D. M., Cheng, T., DePinho, R. A., Sharpless, N. E., & Scadden, D. T. (2006) · Nature · doi:10.1038/nature05159 · Cited by 1,106
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R., & Landfield, P. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308512100 · Cited by 1,025 · cited 1×
“Additional support for a role of tumor suppressors in aging and AD comes from a microarray study, in which an up-regulation of a disproportionately high number of tumor suppressors or tumor suppressor co-factors, including several of the retinoblastoma (Rb) family, were found in the CA1 region of the hippocampus of AD…”
Backgroundp16INK4a induces an age-dependent decline in islet regenerative potential
Krishnamurthy, J., Ramsey, M. R., Ligon, K. L., Torrice, C., Koh, A., Bonner-Weir, S., & Sharpless, N. E. (2006) · Nature · doi:10.1038/nature05092 · Cited by 1,003
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing
Molofsky, A. V., Slutsky, S. G., Joseph, N. M., He, S., Pardal, R., Krishnamurthy, J., Sharpless, N. E., & Morrison, S. J. (2006) · Nature · doi:10.1038/nature05091 · Cited by 972
Yaffe, M. B., Schutkowski, M., Shen, M., Zhou, X. Z., Stukenberg, P. T., Rahfeld, J.-U., Xu, J., Kuang, J., Kirschner, M. W., Fischer, G., et al. (1997) · Science · doi:10.1126/science.278.5345.1957 · Cited by 770 · cited 1×
“Pin1 is conserved from yeast to humans and has been shown to regulate a diverse array of cellular processes of cell proliferation and differentiation, such as cell-cycle control, transcription and splicing regulation, DNA replication checkpoint control, DNA damage response, neuronal survival, and germ cell development…”
BackgroundHow stem cells age and why this makes us grow old
Sharpless, N. E., & DePinho, R. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2241 · Cited by 743 · cited 1×
“After DNA damage, intracellular stress pathways which are able to recognize the damage are activated, and either recruit DNA repair factors to mend the damage, or induce apoptosis or senescence [19].”
BackgroundThe prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721
The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease
Lu, K. P., & Zhou, X. Z. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2261 · Cited by 682 · cited 1×
“Therefore, deletion of the Pin1 gene alone in mice causes progressive deposition of tau and Aβ, and neuronal degeneration [56,60].”
BackgroundCDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 672 · cited 1×
“Perturbations of the Wnt signaling pathway are best known to be involved in colorectal cancer [92,93] and are associated with several other cancers including lung, prostate, breast [92–96].”
BackgroundRyo, A., Suizu, F., Yoshida, Y., Perrem, K., Liou, Y.-C., Wulf, G., Rottapel, R., Yamaoka, S., & Lu, K. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00490-8 · Cited by 637
Regulation of Raf-1 by Direct Feedback Phosphorylation
Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., & Morrison, D. K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.055 · Cited by 633
Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling
Malanchi, I., Peinado, H., Kassen, D., Hussenet, T., Metzger, D., Chambon, P., Huber, M., Hohl, D., Cano, A., Birchmeier, W., et al. (2008) · Nature · doi:10.1038/nature06835 · Cited by 597
β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding
Busciglio, J., Lorenzo, A., Yeh, J., & Yankner, B. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90232-5 · Cited by 595
Modulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586 · cited 1×
“Further support for the role of p53 in accelerating aging comes from a report showing that transgenic mice that overexpress p44 (a protein that enhances p53 activity) have a shortened lifespan and accelerated aging, and an extraordinary low incidence of cancer compared to wild-type mice [29].”
BackgroundZindy, F., Quelle, D. E., Roussel, M. F., & Sherr, C. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201178 · Cited by 574 · cited 1×
“On the other hand, increased levels of p16 expression and of the incidence of p16-positive cells are associated with age in many mouse and rat tissues [48,49].”
BackgroundPin1-Dependent Prolyl Isomerization Regulates Dephosphorylation of Cdc25C and Tau Proteins
Zhou, X. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00085-x · Cited by 544
'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally
García‐Cao, I., García‐Cao, M., Martín‐Caballero, J., Criado, L. M., Klatt, P., Flores, J. M., Weill, J., Blasco, M. A., & Serrano, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf595 · Cited by 529 · cited 1×
“Also, transgenic mouse models with elevated p53 activity, but under normal regulatory control, show reduced tumor formation without accelerated aging [31,32].”
BackgroundWulf, G. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3459 · Cited by 528
Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis
Zhang, Z., Hartmann, H., Minh Do, V., Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., van de Wetering, M., Clevers, H., Saftig, P., et al. (1998) · Nature · doi:10.1038/27208 · Cited by 517
Alzheimer's disease – do tauists and baptists finally shake hands?
Mudher, A., & Lovestone, S. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02031-2 · Cited by 514
The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production
Pastorino, L., Sun, A., Lu, P.-J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.-H., Li, X., et al. (2006) · Nature · doi:10.1038/nature04543 · Cited by 487
p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease
Bae, B.-I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.005 · Cited by 485 · cited 1×
“Elevated p53 levels have been detected in the central nervous system of patients diagnosed with neurodegenerative diseases, such as Huntington’s disease and Amyotrophic Lateral Sclerosis [35,36] and in mouse models [37] and in the brains of Parkinson’s disease patients [38].”
BackgroundAlzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal
Hardy, J. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s317 · Cited by 475 · cited 1×
“The leading explanation for the pathologic changes associated with AD is the “amyloid hypothesis” which states that neuronal dysfunction and death, neurofibrillary degeneration, microglial activation and the full manifestation of Alzheimer pathology are initiated by Aβ deposition [11].”
BackgroundTelomeres, stem cells, senescence, and cancer
Sharpless, N. E., & DePinho, R. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20761 · Cited by 473
Delayed ageing through damage protection by the Arf/p53 pathway
Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J. M., Viña, J., Blasco, M. A., & Serrano, M. (2007) · Nature · doi:10.1038/nature05949 · Cited by 466 · cited 1×
“However, genetically manipulated mice showing increased activity of the Arf/p53 pathway but conserving the normal regulation of p53, show both cancer resistance and decreased aging [30], which is what would be expected if cancer, a major cause of death in mice, is prevented.”
BackgroundAccelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation
Varela, I., Cadiñanos, J., Pendás, A. M., Gutiérrez-Fernández, A., Folgueras, A. R., Sánchez, L. M., Zhou, Z., Rodríguez, F. J., Stewart, C. L., Vega, J. A., et al. (2005) · Nature · doi:10.1038/nature04019 · Cited by 466 · cited 1×
“Additional support for the concept that hyperactivation of the tumor suppressor p53 may be related to accelerated aging comes from a study showing that mice deficient in Zmpste24, a metalloproteinase involved in the maturation of lamin A, show a senescence phenotype at the cellular level and accelerated aging at the o…”
BackgroundRyo, A., Nakamura, M., Wulf, G., Liou, Y.-C., & Lu, K. P. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-793 · Cited by 465
BILLINGSLEY, M. L., & KINCAID, R. L. (1997) · Biochemical Journal · doi:10.1042/bj3230577 · Cited by 453 · cited 1×
“The abnormal phosphorylation of tau in AD and other neurodegenerative disorders induces a decreased capability of tau to promote tubulin polymerization and bind to microtubules [12], leading to a generalized loss of microtubule stability [13] and eventually retrograde neurodegeneration.”
BackgroundAlonso, A. D. C., Grundke-Iqbal, I., Barra, H. S., & Iqbal, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.298 · Cited by 437 · cited 1×
“The abnormal phosphorylation of tau in AD and other neurodegenerative disorders induces a decreased capability of tau to promote tubulin polymerization and bind to microtubules [12], leading to a generalized loss of microtubule stability [13] and eventually retrograde neurodegeneration.”
BackgroundRole of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration
Liou, Y.-C., Sun, A., Ryo, A., Zhou, X. Z., Yu, Z.-X., Huang, H.-K., Uchida, T., Bronson, R., Bing, G., Li, X., et al. (2003) · Nature · doi:10.1038/nature01832 · Cited by 435
A complex barcode underlies the heterogeneous response of p53 to stress
Murray-Zmijewski, F., Slee, E. A., & Lu, X. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2451 · Cited by 420 · cited 3×
“The p53 gene is the prototypical tumor suppressor and its pathway is inactivated in most human cancers [18].”
BackgroundThe prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults
Zacchi, P., Gostissa, M., Uchida, T., Salvagno, C., Avolio, F., Volinia, S., Ronai, Z., Blandino, G., Schneider, C., & Sal, G. D. (2002) · Nature · doi:10.1038/nature01120 · Cited by 414 · cited 1×
“Cells lacking Pin1 fail to efficiently stabilize p53 and are then able to escape cell cycle arrest and apoptotic responses [83,85], thus promoting the ‘prone to cancer’ direction in figure 1.”
Backgroundp53 suppresses the self-renewal of adult neural stem cells
Meletis, K., Wirta, V., Hede, S.-M., Nistér, M., Lundeberg, J., & Frisén, J. (2006) · Development · doi:10.1242/dev.02208 · Cited by 413 · cited 1×
“knocked out p53 mice (p53−/−) have a significantly higher number of proliferating cells, as assessed by the incorporation of the nucleotide analogue bromodeoxyuridine in the lateral ventricle wall, compared to wild-type littermates [25].”
BackgroundCaricasole, A., Copani, A., Caraci, F., Aronica, E., Rozemuller, A. J., Caruso, A., Storto, M., Gaviraghi, G., Terstappen, G. C., & Nicoletti, F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1381-04.2004 · Cited by 398
Critical pathways in cellular senescence and immortalization revealed by gene expression profiling
Fridman, A. L., & Tainsky, M. A. (2008) · Oncogene · doi:10.1038/onc.2008.213 · Cited by 385 · cited 1×
“tumors including acute lymphoblastic leukemia of childhood, melanomas, gliomas, as well as carcinoma of the pancreas, esophagus, lung, bladder, head, and neck [46,47].”
BackgroundPrevalent Overexpression of Prolyl Isomerase Pin1 in Human Cancers
Bao, L., Kimzey, A., Sauter, G., Sowadski, J. M., Lu, K. P., & Wang, D.-G. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63731-5 · Cited by 378 · cited 1×
“A prevalent overexpression of Pin1 has been shown in most human cancers including prostate, breast, lung, colon and liver [73–76], but not in others such as renal cancer [77].”
BackgroundLithium and risk for Alzheimer's disease in elderly patients with bipolar disorder
Nunes, P. V., Forlenza, O. V., & Gattaz, W. F. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.029868 · Cited by 368
De Ferrari, G. V., Chacón, M. A., Barría, M. I., Garrido, J. L., Godoy, J. A., Olivares, G., Reyes, A. E., Alvarez, A., Bronfman, M., & Inestrosa, N. C. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001208 · Cited by 332 · cited 1×
“pathway, protected rat hippocampal neurons from Abeta-induced damage [109].”
BackgroundLinking Calcium to Aβ and Alzheimer's Disease
Green, K. N., & LaFerla, F. M. (2008) · Neuron · doi:10.1016/j.neuron.2008.07.013 · Cited by 326
E2F – at the crossroads of life and death
Polager, S., & Ginsberg, D. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.003 · Cited by 302 · cited 1×
“tumors including acute lymphoblastic leukemia of childhood, melanomas, gliomas, as well as carcinoma of the pancreas, esophagus, lung, bladder, head, and neck [46,47].”
BackgroundAlzheimer Disease and Mortality: A 15-Year Epidemiological Study
Ganguli, M., Dodge, H. H., Shen, C., Pandav, R. S., & DeKosky, S. T. (2005) · Archives of Neurology · doi:10.1001/archneur.62.5.779 · Cited by 297
Wnt signaling function in Alzheimer’s disease
De Ferrari and, G. V., & Inestrosa, N. C. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00021-7 · Cited by 289
Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate
Knights, C. D., Catania, J., Giovanni, S. D., Muratoglu, S., Perez, R., Swartzbeck, A., Quong, A. A., Zhang, X., Beerman, T., Pestell, R. G., et al. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200512059 · Cited by 287 · cited 1×
“For example, depending on the tissue, the same acetylation of the Lys amino acid at position 320 of p53 can promote neurite outgrowth in neuronal cells [33] or cell cycle arrest in other tissues [34].”
BackgroundTakashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287
Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease
Ohyagi, Y., Asahara, H., Chui, D.-H., Tsuruta, Y., Sakae, N., Miyoshi, K., Yamada, T., Kikuchi, H., Taniwaki, T., Murai, H., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2637fje · Cited by 281
The significance of the Wnt pathway in the pathology of human cancers
Karim, R. Z., Tse, G. M. K., Putti, T. C., Scolyer, R. A., & Soon Lee, C. (2004) · Pathology · doi:10.1080/00313020410001671957 · Cited by 276
De Ferrari, G. V., Papassotiropoulos, A., Biechele, T., Wavrant De-Vrieze, F., Avila, M. E., Major, M. B., Myers, A., Sáez, K., Henríquez, J. P., Zhao, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603523104 · Cited by 270
Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J., Pierce, W. M., Klein, J. B., Markesbery, W. R., Zhou, X. Z., Lu, K. P., & Butterfield, D. A. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.005 · Cited by 253 · cited 1×
“In accordance with these results downregulation of Pin1 has been reported in the hippocampus of AD patients [64].”
Resultp53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain
Mogi, M., Kondo, T., Mizuno, Y., & Nagatsu, T. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.12.003 · Cited by 242
Pinning down cell signaling, cancer and Alzheimer's disease
Lu, K. P. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.02.002 · Cited by 237 · cited 1×
“Aberrant Pin1 function has been implicated in both cancer and AD [57, 58].”
BackgroundThe tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration
Di Giovanni, S., Knights, C. D., Rao, M., Yakovlev, A., Beers, J., Catania, J., Avantaggiati, M. L., & Faden, A. I. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601292 · Cited by 226 · cited 1×
“For example, depending on the tissue, the same acetylation of the Lys amino acid at position 320 of p53 can promote neurite outgrowth in neuronal cells [33] or cell cycle arrest in other tissues [34].”
BackgroundLi, H.-L., Wang, H.-H., Liu, S.-J., Deng, Y.-Q., Zhang, Y.-J., Tian, Q., Wang, X.-C., Chen, X.-Q., Yang, Y., Zhang, J.-Y., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609303104 · Cited by 225
Roe, C. M., Behrens, M. I., Xiong, C., Miller, J. P., & Morris, J. C. (2005) · Neurology · doi:10.1212/01.wnl.0000152889.94785.51 · Cited by 223
Self-citationThe ups and downs of Wnt signaling in prevalent neurological disorders
De Ferrari, G. V., & Moon, R. T. (2006) · Oncogene · doi:10.1038/sj.onc.1210064 · Cited by 222
Magdesian, M. H., Carvalho, M. M. V. F., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L., Garcia-Abreu, J., & Ferreira, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707108200 · Cited by 221
Wnt-3a overcomes β-amyloid toxicity in rat hippocampal neurons
Alvarez, A. R., Godoy, J. A., Mullendorff, K., Olivares, G. H., Bronfman, M., & Inestrosa, N. C. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.02.028 · Cited by 213
Wnt signaling in neuroprotection and stem cell differentiation
Toledo, E. M., Colombres, M., & Inestrosa, N. C. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.08.001 · Cited by 211
Tumor suppression and normal aging in mice with constitutively high p53 activity
Mendrysa, S. M., O'Leary, K. A., McElwee, M. K., Michalowski, J., Eisenman, R. N., Powell, D. A., & Perry, M. E. (2006) · Genes & Development · doi:10.1101/gad.1378506 · Cited by 210 · cited 1×
“Also, transgenic mouse models with elevated p53 activity, but under normal regulatory control, show reduced tumor formation without accelerated aging [31,32].”
BackgroundCause of death in Alzheimer's disease
Beard, C. M., Kokmen, E., Sigler, C., Smith, G. E., Petterson, T., & O'Brien, P. C. (1996) · Annals of Epidemiology · doi:10.1016/1047-2797(95)00068-2 · Cited by 209
Atypical cancer pattern in patients with Parkinson's disease
Olsen, J. H., Friis, S., Frederiksen, K., McLaughlin, J. K., Mellemkjaer, L., & Møller, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602279 · Cited by 209
The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease
Inestrosa, N. C., & Toledo, E. M. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-9 · Cited by 206
Hoseong Yang, S., Andl, T., Grachtchouk, V., Wang, A., Liu, J., Syu, L.-J., Ferris, J., Wang, T. S., Glick, A. B., Millar, S. E., et al. (2008) · Nature Genetics · doi:10.1038/ng.192 · Cited by 195
Mukherjee, O., Pastor, P., Cairns, N. J., Chakraverty, S., Kauwe, J. S. K., Shears, S., Behrens, M. I., Budde, J., Hinrichs, A. L., Norton, J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20963 · Cited by 187
Self-citationLombardi, V. R. M., Garcı́a, M., Rey, L., & Cacabelos, R. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00046-6 · Cited by 182
Mantovani, F., Tocco, F., Girardini, J. E., Smith, P., Gasco, M., Lü, X., Crook, T., & Sal, G. D. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1306 · Cited by 181 · cited 1×
“Cells lacking Pin1 fail to efficiently stabilize p53 and are then able to escape cell cycle arrest and apoptotic responses [83,85], thus promoting the ‘prone to cancer’ direction in figure 1.”
BackgroundAging, tumor suppression and cancer: high wire-act!
Campisi, J. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.09.024 · Cited by 171 · cited 1×
“Thus, tumor suppressor mechanisms may be an example of evolutionary antagonistic pleiotropy [21,22, 23], that is, they promote early-life survival by preventing the development of cancer, but eventually limiting longevity.”
BackgroundThe Wnt signaling pathway: Aging gracefully as a protectionist?
Maiese, K., Li, F., Chong, Z. Z., & Shang, Y. C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.01.004 · Cited by 170
WNT5A Expression Increases during Melanoma Progression and Correlates with Outcome
Da Forno, P. D., Pringle, J. H., Hutchinson, P., Osborn, J., Huang, Q., Potter, L., Hancox, R. A., Fletcher, A., & Saldanha, G. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5104 · Cited by 170
Presenilin-Dependent -Secretase-Mediated Control of p53-Associated Cell Death in Alzheimer's Disease
Alves da Costa, C., Sunyach, C., Pardossi-Piquard, R., Sevalle, J., Vincent, B., Boyer, N., Kawarai, T., Girardot, N., St. George-Hyslop, P., & Checler, F. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0651-06.2006 · Cited by 168
p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells
Hooper, C., Meimaridou, E., Tavassoli, M., Melino, G., Lovestone, S., & Killick, R. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.026 · Cited by 165 · cited 1×
“Several reports have described upregulation of p53 in the brains of patients with AD [41,42,43].”
BackgroundYamada, M., Sasaki, H., Mimori, Y., Kasagi, F., Sudoh, S., Ikeda, J., Hosoda, Y., Nakamura, S., & Kodama, K. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb04577.x · Cited by 156
Cancino, G. I., Toledo, E. M., Leal, N. R., Hernandez, D. E., Yévenes, L. F., Inestrosa, N. C., & Alvarez, A. R. (2008) · Brain · doi:10.1093/brain/awn125 · Cited by 147
Ong, C., & Bateman, A. (2003) · PubMed · doi:10.14670/hh-18.1275 · Cited by 138
Pang, R. W. C., Lee, T. K., Poon, R. T. P., Fan, S. T., Wong, K., Kwong, Y., & Tse, E. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.12.030 · Cited by 137
van Drogen, F., Sangfelt, O., Malyukova, A., Matskova, L. V., Yeh, E. S., Means, A. R., & Reed, S. I. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.020 · Cited by 136
Fiorentino, M., Zadra, G., Palescandolo, E., Fedele, G., Bailey, D., Fiore, C., Nguyen, P. L., Migita, T., Zamponi, R., Di Vizio, D., et al. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.97 · Cited by 136
p53 Is Abnormally Elevated and Active in the CNS of Patients with Amyotrophic Lateral Sclerosis
Martin, L. J. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0314 · Cited by 135 · cited 1×
“Elevated p53 levels have been detected in the central nervous system of patients diagnosed with neurodegenerative diseases, such as Huntington’s disease and Amyotrophic Lateral Sclerosis [35,36] and in mouse models [37] and in the brains of Parkinson’s disease patients [38].”
BackgroundLithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease
Mendes, C. T., Mury, F. B., Moreira, E. D. S., Alberto, F., Forlenza, O. V., Dias‐Neto, E., & Gattaz, W. F. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0828-5 · Cited by 126
Some p53-binding proteins that can function as arbiters of life and death
Braithwaite, A. W., Sal, G. D., & Lü, X. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401924 · Cited by 121 · cited 1×
“Accumulating evidence suggests that Pin1 regulates the timing of p53 activation, modulating its interaction with DNA and cofactors [84].”
BackgroundSuizu, F., Ryo, A., Wulf, G., Lim, J., & Lu, K. P. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1463-1479.2006 · Cited by 118
To die or grow: Parkinson's disease and cancer
WEST, A., DAWSON, V, & DAWSON, T. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.05.002 · Cited by 117
Cenini, G., Sultana, R., Memo, M., & Butterfield, D. A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00163.x · Cited by 117 · cited 1×
“Several reports have described upregulation of p53 in the brains of patients with AD [41,42,43].”
BackgroundPin1 has opposite effects on wild-type and P301L tau stability and tauopathy
Lim, J., Balastik, M., Lee, T. H., Nakamura, K., Liou, Y.-C., Sun, A., Finn, G., Pastorino, L., Lee, V. M.-Y., & Lu, K. P. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34308 · Cited by 116
Extracellular deposition of beta-amyloid upon p53-dependent neuronal cell death in transgenic mice.
LaFerla, F. M., Hall, C. K., Ngo, L., & Jay, G. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118957 · Cited by 114 · cited 1×
“The intracellular expression of the Aβ protein under a neuron-specific promoter led progressively to degeneration and death of neurons in the brains of transgenic mice and Aβ accumulation was correlated with activation of p53 [39].”
BackgroundPIN1 promoter polymorphisms are associated with Alzheimer's disease
Segat, L., Pontillo, A., Annoni, G., Trabattoni, D., Vergani, C., Clerici, M., Arosio, B., & Crovella, S. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.11.009 · Cited by 110
Veeck, J., Bektas, N., Hartmann, A., Kristiansen, G., Heindrichs, U., Knüchel, R., & Dahl, E. (2008) · Breast Cancer Research · doi:10.1186/bcr2151 · Cited by 106
Takahashi, K., Uchida, C., Shin, R.-W., Shimazaki, K., & Uchida, T. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7270-0 · Cited by 105 · cited 1×
“Aberrant Pin1 function has been implicated in both cancer and AD [57, 58].”
BackgroundInhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells
Caruso, A., Motolese, M., Iacovelli, L., Caraci, F., Copani, A., Nicoletti, F., Terstappen, G. C., Gaviraghi, G., & Caricasole, A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03867.x · Cited by 101
Pin1 allows for differential Tau dephosphorylation in neuronal cells
Hamdane, M., Dourlen, P., Bretteville, A., Sambo, A., Ferreira, S., Ando, K., Kerdraon, O., Bégard, S., Geay, L., Lippens, G. M., et al. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2006.03.006 · Cited by 94
MENTAL ILLNESS AND THE AGEING BRAIN
Cumings, J. N. (1963) · Journal of Clinical Pathology · doi:10.1136/jcp.16.1.98-c · Cited by 93
Buongiorno, P., Pethe, V. V., Charames, G. S., Esufali, S., & Bapat, B. V. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-73 · Cited by 84 · cited 1×
“Perturbations of the Wnt signaling pathway are best known to be involved in colorectal cancer [92,93] and are associated with several other cancers including lung, prostate, breast [92–96].”
BackgroundTwo Sides of the Same Coin: Wnt Signaling in Neurodegeneration and Neuro-Oncology
Caricasole, A., Bakker, A., Copani, A., Nicoletti, F., Gaviraghi, G., & Terstappen, G. C. (2005) · Bioscience Reports · doi:10.1007/s10540-005-2893-6 · Cited by 76 · cited 1×
“Therefore, defects in wnt signaling have been proposed in the pathogenesis of AD [90,114,115].”
BackgroundGhanevati, M., & Miller, C. A. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:25:1:079 · Cited by 73
p53: at the crossroad between cancer and ageing
Papazoglu, C., & Mills, A. (2007) · The Journal of Pathology · doi:10.1002/path.2086 · Cited by 72 · cited 1×
“Thus, tumor suppressor mechanisms may be an example of evolutionary antagonistic pleiotropy [21,22, 23], that is, they promote early-life survival by preventing the development of cancer, but eventually limiting longevity.”
BackgroundEvidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2.
Wijsman, E. M., Daw, E. W., Yu, C.-E., Payami, H., Steinbart, E. J., Nochlin, D., Conlon, E. M., Bird, T. D., & Schellenberg, G. D. (2004) · The American Journal of Human Genetics · doi:10.1086/423393 · Cited by 71
Synaptotoxicity in Alzheimer's Disease: The Wnt Signaling Pathway as a Molecular Target
Inestrosa, N. C., Varela‐Nallar, L., Grabowski, C. P., & Colombres, M. (2007) · IUBMB Life · doi:10.1080/15216540701242490 · Cited by 67
Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer
Coe, B. P., Lockwood, W. W., Girard, L., Chari, R., MacAulay, C., Lam, S., Gazdar, A. F., Minna, J. D., & Lam, W. L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603167 · Cited by 67
Tumorigenesis and neurodegeneration: two sides of the same coin?
Staropoli, J. F. (2008) · BioEssays · doi:10.1002/bies.20784 · Cited by 67
Wnt Signaling in Development, Disease and Translational Medicine
Coombs, G. S., Covey, T. M., & Virshup, D. M. (2008) · Current Drug Targets · doi:10.2174/138945008784911796 · Cited by 63 · cited 2×
“The Wnt (wingless-type murine-mammary tumour virus integration site) signaling pathway is important for many developmental and adult processes, such as gastrulation, axis formation, cell polarity, organ development and maintenance of stem cell pluripotency and is remarkably conserved in a wide range of organisms, from…”
BackgroundMartin, L. J. (2007) · Reviews in the Neurosciences · doi:10.1515/revneuro.2007.18.2.115 · Cited by 62 · cited 1×
“Elevated p53 levels have been detected in the central nervous system of patients diagnosed with neurodegenerative diseases, such as Huntington’s disease and Amyotrophic Lateral Sclerosis [35,36] and in mouse models [37] and in the brains of Parkinson’s disease patients [38].”
BackgroundBehrens, M. I., Mukherjee, O., Tu, P.-H., Liscic, R. M., Grinberg, L. T., Carter, D., Paulsmeyer, K., Taylor-Reinwald, L., Gitcho, M., Norton, J. B., et al. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31803083f2 · Cited by 58
Self-citationKesavapany, S., Patel, V., Zheng, Y., Pareek, T. K., Bjelogrlic, M., Albers, W., Amin, N. D., Jaffe, H., Gutkind, J. S., Strong, M. J., et al. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-03-0237 · Cited by 56 · cited 1×
“Evidence for a participation of Pin1 in ALS has also been reported [72].”
BackgroundMortality cancer risk in parkinsonian patients: A population-based study
Riggs, J. E., Vanacore, N., Spila-Alegiani, S., Raschetti, R., & Meco, G. (1999) · Neurology · doi:10.1212/wnl.53.5.1158-a · Cited by 53
Aging and cancer cell biology, 2008
Campisi, J. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00383.x · Cited by 50
Asplund, A., Gry, M., Sundquist, C., Strömberg, S., Edlund, K., Östman, A., Nilsson, P., Pontén, F., & Lundeberg, J. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08418.x · Cited by 49
He, J., Zhou, F., Shao, K., Hang, J., Wang, H., Rayburn, E. R., Xiao, Z. J., Lee, S. W., Xue, Q., Feng, X.-L., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.11.024 · Cited by 45
The Significance of Pin1 in the Development of Alzheimer's Disease
Wang, S., Simon, B. P., Bennett, D. A., Schneider, J. A., Malter, J. S., & Wang, D.-S. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11105 · Cited by 39 · cited 2×
“In contrast, the opposite was found with mutant P301L tau; Pin1 knockdown or KO decreased P301L tau protein stability and abolished its robust tauopathy phenotype in the mutant mice, whereas its overexpression exacerbated the tauopathy phenotype in P301L tau mice [65].”
BackgroundResultKim, M. R., Choi, H. S., Heo, T., Hwang, S. W., & Kang, K. W. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.045 · Cited by 38
The Relationship between Cancer and Alzheimer's Disease
Tirumalasetti, F., Han, L., & Birkett, D. P. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb02713.x · Cited by 36
Conformationally Altered p53: A Putative Peripheral Marker for Alzheimer’s Disease
Uberti, D., Lanni, C., Racchi, M., Govoni, S., & Memo, M. (2008) · Neurodegenerative Diseases · doi:10.1159/000113704 · Cited by 34
Tumor diagnosis preceding Parkinson's disease: A case–control study
D'Amelio, M., Ragonese, P., Morgante, L., Epifanio, A., Callari, G., Salemi, G., & Savettieri, G. (2004) · Movement Disorders · doi:10.1002/mds.20123 · Cited by 34
Wnt signaling and senescence: A tug of war in early neoplasia?
Adams, P. D., & Enders, G. H. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.11.6943 · Cited by 26
Association study of the PIN1 gene with Alzheimer's disease
Lambert, J., Bensemain, F., Chapuis, J., Cottel, D., & Amouyel, P. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.04.010 · Cited by 26
Becker, E. B. E., & Bonni, A. (2007) · Cell Cycle · doi:10.4161/cc.6.11.4316 · Cited by 26 · cited 1×
“Also, a role of Pin1 in promoting the mitochondrial apoptotic machinery has been described in neurons [86,87].”
BackgroundNowotny, P., Bertelsen, S. E., Hinrichs, A. L., Kauwe, J. S. K., Mayo, K., Jacquart, S., Morris, J. C., & Goate, A. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.071 · Cited by 25
Mutant presenilin 2 increased oxidative stress and p53 expression in neuronal cells
Nguyen, H. N., Lee, M. S., Hwang, D. Y., Kim, Y. K., Yoon, D. Y., Lee, J. W., Yun, Y. P., Lee, M. K., Oh, K. W., & Hong, J. T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.119 · Cited by 24 · cited 1×
“Mutations in the presenilins cause familial forms of AD and have also been shown to trigger p53-dependent cell death [44,45].”
BackgroundPin1 promotes cell death in NGF‐dependent neurons through a mechanism requiring c‐Jun activity
Barone, M. C., Desouza, L. A., & Freeman, R. S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05427.x · Cited by 23 · cited 1×
“Also, a role of Pin1 in promoting the mitochondrial apoptotic machinery has been described in neurons [86,87].”
BackgroundThe Relationship between Cancer and Alzheimer's Disease
Desouky, A. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb04490.x · Cited by 21
Tremolizzo, L., Rodriguez‐Menendez, V., Brighina, L., & Ferrarese, C. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.12.022 · Cited by 20
DNA sequence variations in the prolyl isomerase Pin1 gene and Alzheimer's disease
Poli, M., Gatta, L. B., Dominici, R., Lovati, C., Mariani, C. B., Albertini, A., & Finazzi, D. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.07.027 · Cited by 15
Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation
Skoglund, L., Brundin, R., Olofsson, T., Kalimo, H., Ingvast, S., Blom, E. S., Giedraitis, V., Ingelsson, M., Lannfelt, L., Basun, H., et al. (2008) · Neurogenetics · doi:10.1007/s10048-008-0155-z · Cited by 15
Inverse Association between Cancer and Dementia of the Alzheimer’s Type
Pellegrino, M. I. B., Roe, C. M., & Morris, J. C. (2008) · Universidad de Chile · Cited by 5
Self-citation
Cited by
Targeting Free Radicals in Oxidative Stress-Related Human Diseases
Poprac, P., Jomova, K., Simunkova, M., Kollar, V., Rhodes, C. J., & Valko, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.005 · Cited by 1,107
Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study
Driver, J. A., Beiser, A., Au, R., Kreger, B. E., Splansky, G. L., Kurth, T., Kiel, D. P., Lu, K. P., Seshadri, S., & Wolf, P. A. (2012) · BMJ · doi:10.1136/bmj.e1442 · Cited by 425
Peptidyl-prolyl cis–trans isomerase Pin1 in ageing, cancer and Alzheimer disease
Lee, T. H., Pastorino, L., & Lu, K. P. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001906 · Cited by 181
DNA methylation as a universal biomarker
Levenson, V. V. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.17 · Cited by 166
Rosen, E. Y., Wexler, E. M., Versano, R., Coppola, G., Gao, F., Winden, K. D., Oldham, M. C., Martens, L. H., Zhou, P., Farese, R. V., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.021 · Cited by 128
Metadata
- Authors
- Behrens, M., Lendon, C., & Roe, C.
- Venue
- Current Alzheimer Research
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-06-01
- Volume
- 6
- Issue
- 3
- Pages
- 196-204
- ISSN
- 1567-2050 (ISSN-L)
- OpenAlex
- W2170197381
- Cited by
- 184
- References
- 131
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.